Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

WISCONSIN: Treatment of Hepatitis C Can Be Successful in a Prison Population




 

News-Medical.net (10.08.12)

Study results are currently showing that incarcerated individuals with chronic hepatitis C virus (HCV) infection can be successfully treated with pegylated interferon and ribavirin, and have achieved comparable rates of treatment completion and sustained viral response to those outside the correctional setting. HCV infection within incarcerated populations has reached as high as 31 percent, compared with 1.6 percent of the general population, leading researchers to suggest that anti-viral treatment while incarcerated is optimal. No study had compared treatment with pegylated interferon and ribavirin between contemporaneous incarcerated and community patients treated at the same clinic until Michael Lucey (University of Wisconsin, Madison, USA) and colleagues evaluated 388 incarcerated and 521 nonincarcerated HCV-infected patients for treatment at the University of Wisconsin clinics between January of 2002 and December of 2007. Overall, 386 (69.8 percent) patients completed a full treatment course, and a similar proportion of incarcerated and nonincarcerated completed a full treatment course (75 percent and 68.6 percent, respectively). Additionally, a sustained viral response (SVR) was achieved in a similar number of both incarcerated (42.9 percent) and nonincarcerated (38 percent) patients. The study shows that prison offers potential access to appropriate HCV care for a population with numerous socioeconomic, psychiatric, and substance abuse factors.



 


Copyright © 2012 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in October 10, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.